Gene · 8019
Papers2,104
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
401 to 420 of 2,104
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Discovery of E3 Ligase Ligands for Target Protein Degradation. | Molecules | 2022 | 36235052 | PubTator, text mining | PubMed |
| Enhancer RNA (eRNA) in Human Diseases. | Int J Mol Sci | 2022 | 36232885 | PubTator, text mining | PubMed |
| Sequence Analysis of Novel Staphylococcus aureus Lineages from Wild and Captive Macaques. | Int J Mol Sci | 2022 | 36232529 | PubTator, text mining | PubMed |
| Influence of Shear Stress, Inflammation and BRD4 Inhibition on Human Endothelial Cells: A Holistic Proteomic Approach. | Cells | 2022 | 36231049 | PubTator, text mining | PubMed |
| Combination bromo- and extraterminal domain and poly (ADP-ribose) polymerase inhibition synergistically enhances DNA damage and inhibits neuroblastoma tumorigenesis. | Discov Oncol | 2022 | 36227363 | PubTator, text mining | PubMed |
| Selective and Cell-Active PBRM1 Bromodomain Inhibitors Discovered through NMR Fragment Screening. | J Med Chem | 2022 | 36227159 | PubTator, text mining | PubMed |
| Current understanding of epigenetics role in melanoma treatment and resistance. | Cancer Cell Int | 2022 | 36224606 | PubTator, text mining | PubMed |
| An inhibitor of BRD4, GNE987, inhibits the growth of glioblastoma cells by targeting C-Myc and S100A16. | Cancer Chemother Pharmacol | 2022 | 36224471 | PubTator, text mining | PubMed |
| Acute pharmacological degradation of ERK5 does not inhibit cellular immune response or proliferation. | Cell Chem Biol | 2022 | 36220104 | PubTator, text mining | PubMed |
| Ex vivo exposures to arsenite and its methylated trivalent metabolites alter gene transcription in mouse sperm cells. | Toxicol Appl Pharmacol | 2022 | 36209798 | PubTator, text mining | PubMed |
| Toward more potent imidazopyridine inhibitors of Candida albicans Bdf1: Modeling the role of structural waters in selective ligand binding. | J Comput Chem | 2022 | 36190786 | PubTator, text mining | PubMed |
| Histone modification and histone modification-targeted anti-cancer drugs in breast cancer: Fundamentals and beyond. | Front Pharmacol | 2022 | 36188615 | PubTator, text mining | PubMed |
| Targeting bromodomain and extra-terminal proteins to inhibit neuroblastoma tumorigenesis through regulating MYCN. | Front Cell Dev Biol | 2022 | 36187481 | PubTator, text mining | PubMed |
| Clustering of Chromatin Remodeling Enzymes Predicts Prognosis and Clinical Benefit of Therapeutic Strategy in Pancreatic Cancer. | Int J Med Sci | 2022 | 36185333 | PubTator, text mining | PubMed |
| N-terminal BET bromodomain inhibitors disrupt a BRD4-p65 interaction and reduce inducible nitric oxide synthase transcription in pancreatic β-cells. | Front Endocrinol (Lausanne) | 2022 | 36176467 | PubTator, text mining | PubMed |
| The role of protein acetylation in carcinogenesis and targeted drug discovery. | Front Endocrinol (Lausanne) | 2022 | 36171897 | PubTator, text mining | PubMed |
| BRD4 PROTAC degrader MZ1 exerts anticancer effects in acute myeloid leukemia by targeting c-Myc and ANP32B genes. | Cancer Biol Ther | 2022 | 36170346 | PubTator, text mining | PubMed |
| An interplay between BRD4 and G9a regulates skeletal myogenesis. | Front Cell Dev Biol | 2022 | 36158208 | PubTator, text mining | PubMed |
| Super enhancers: Pathogenic roles and potential therapeutic targets for acute myeloid leukemia (AML). | Genes Dis | 2022 | 36157504 | PubTator, text mining | PubMed |
| Cross-Ancestry Investigation of Venous Thromboembolism Genomic Predictors. | Circulation | 2022 | 36154123 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8019/papers?page=21